US Stock MarketDetailed Quotes

ADMA ADMA Biologics

Watchlist
  • 16.390
  • +0.950+6.15%
Close Feb 28 16:00 ET
  • 16.440
  • +0.050+0.31%
Post 20:01 ET
3.87BMarket Cap60.70P/E (TTM)

ADMA Biologics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

ADMA Biologics Q4 2024 Estimates Date

Currency：USDMar 3, 2025

Estimate YoY
Revenue
112.80M
+52.63%
EPS
0.15
+287.73%
Analyst Rating
Buy

Mar 1, 2025

ADMA Biologics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 108.650M--
Mar 3, 20252024/Q4-- / 112.800M--
Nov 7, 20242024/Q3119.839M / 105.850M--
Aug 8, 20242024/Q2107.191M / 86.413M--
May 9, 20242024/Q181.875M / 77.275M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 108.650M--
Mar 3, 20252024/Q4-- / 112.800M--
Nov 7, 20242024/Q3119.839M / 105.850M--
Aug 8, 20242024/Q2107.191M / 86.413M--
May 9, 20242024/Q181.875M / 77.275M--

Unlock Free Earnings Estimates

ADMA Biologics Earnings Reports

  • ADMA Biologics | 10-Q: Q3 2024 Earnings Report

    Nov 7, 2024 17:08 ET

  • ADMA Biologics | 8-K: ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update

    Nov 7, 2024 16:18 ET

  • ADMA Biologics | 10-Q: Q2 2024 Earnings Report

    Aug 8, 2024 17:06 ET

  • ADMA Biologics | 8-K: ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update

    Aug 8, 2024 16:15 ET

    • Read more

    Trending Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Cars.com
    CARS
    +9.73%
    Lantheus
    LNTH
    +2.55%
    Halozyme Therapeutics
    HALO
    +2.51%
    DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
    DMZPY
    +2.27%
    Collegium Pharmaceutical
    COLL
    +2.22%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Mar 1, 2025

    Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data